Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: An efficacy–tolerability pilot study

Emiliano Petrò, Elena Ruffini, Melania Cappuccio, Valeria Guerini, Gloria Belotti, Sara Fascendini, Cristina Licini, Claudio Marcassa

Research output: Contribution to journalArticle

Abstract

Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and naïve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30% from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4% of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P

Original languageEnglish
Pages (from-to)559-569
Number of pages11
JournalNeuropsychiatric Disease and Treatment
Volume12
DOIs
Publication statusPublished - Mar 2 2016

Fingerprint

Oxycodone
Naloxone
Chronic Pain
Pain Measurement
Pain
Dementia
Activities of Daily Living
Nursing Homes
Opioid Analgesics
Alzheimer Disease
Safety
Equipment and Supplies
Cognitive Dysfunction

Keywords

  • Alzheimer’s disease
  • Cognitive impairment
  • Dementia
  • Elderly
  • Oxycodone/naloxone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment : An efficacy–tolerability pilot study. / Petrò, Emiliano; Ruffini, Elena; Cappuccio, Melania; Guerini, Valeria; Belotti, Gloria; Fascendini, Sara; Licini, Cristina; Marcassa, Claudio.

In: Neuropsychiatric Disease and Treatment, Vol. 12, 02.03.2016, p. 559-569.

Research output: Contribution to journalArticle

Petrò, Emiliano ; Ruffini, Elena ; Cappuccio, Melania ; Guerini, Valeria ; Belotti, Gloria ; Fascendini, Sara ; Licini, Cristina ; Marcassa, Claudio. / Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment : An efficacy–tolerability pilot study. In: Neuropsychiatric Disease and Treatment. 2016 ; Vol. 12. pp. 559-569.
@article{b778787f4e1a4fc0a8a9303993e23919,
title = "Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: An efficacy–tolerability pilot study",
abstract = "Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and na{\"i}ve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30{\%} from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4{\%} of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P",
keywords = "Alzheimer’s disease, Cognitive impairment, Dementia, Elderly, Oxycodone/naloxone",
author = "Emiliano Petr{\`o} and Elena Ruffini and Melania Cappuccio and Valeria Guerini and Gloria Belotti and Sara Fascendini and Cristina Licini and Claudio Marcassa",
year = "2016",
month = "3",
day = "2",
doi = "10.2147/NDT.S98511",
language = "English",
volume = "12",
pages = "559--569",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment

T2 - An efficacy–tolerability pilot study

AU - Petrò, Emiliano

AU - Ruffini, Elena

AU - Cappuccio, Melania

AU - Guerini, Valeria

AU - Belotti, Gloria

AU - Fascendini, Sara

AU - Licini, Cristina

AU - Marcassa, Claudio

PY - 2016/3/2

Y1 - 2016/3/2

N2 - Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and naïve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30% from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4% of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P

AB - Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and naïve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30% from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4% of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P

KW - Alzheimer’s disease

KW - Cognitive impairment

KW - Dementia

KW - Elderly

KW - Oxycodone/naloxone

UR - http://www.scopus.com/inward/record.url?scp=84960194006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960194006&partnerID=8YFLogxK

U2 - 10.2147/NDT.S98511

DO - 10.2147/NDT.S98511

M3 - Article

AN - SCOPUS:84960194006

VL - 12

SP - 559

EP - 569

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -